Teaching old drugs new tricks: Reincarnating immunosuppressants as antifungal drugs

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 192-199

  Blankenship, Jill R ^a   Steinbach, William J ^a   Perfect, John R ^a   Heitman, Joseph ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Aspergillus; Candida albicans; Cryptococcus neoformans; Cyclosporin A; FK 506; Immunophilins; Rapamycin

Indexed keywords

ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; FENPROPIMORPH; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; L 685818; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA ALBICANS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DRUG POTENTIATION; DRUG TARGETING; FUNGUS ISOLATION; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NONHUMAN; PREVALENCE; RESTENOSIS; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CALCINEURIN; CYCLOSPORINE; FUNGI; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; SIROLIMUS; TACROLIMUS;

EID: 0344687374     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science (1984) 226(4674):544-547.
2. Takahashi N, Hayano T, Suzuki M: Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 337(6206):473-475.
3. Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 341(6244):758-760.
4. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 66(4):807-815.
5. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 253(5022):905-909.
6. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J: Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 12(4):583-611.
7. Dickman DA, Ding H, Li Q, Nilius AM, Balli DJ, Ballaron SJ, Trevillyan JM, Smith ML, Seif LS, Kim K, Sarthy A et al: Antifungal rapamycin analogues with reduced immunosuppressive activity. Bioorg Med Chem Lett (2000) 10(13):1405-1408.
8. Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J: Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 45(11):3162-3170. This paper provides a detailed genetic analysis of the action of rapamycin and its analogs on C albicans and C neoformans.
9. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, Cardenas ME, Perfect JR, McCusker JH, Heitman J: Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 21(4):546-559. This paper provides a detailed genetic analysis of the fungicidal synergism between azoles and calcineurin inhibitors in Candida species highlighting the importance of calcineurin inhibition for synergy.
10. Odom A, Poeta MD, Perfect J, Heitman J: The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother (1997) 41(1):156-161.
11. Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VFJ, Movva NR, Perfect JR, Cardenas ME, Heitman J: Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 44(1):143-149. Demonstration of the effectiveness of CsA and less immunossuppressive CsA analogs against C neformans and their mechanism of action.
12. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 51(2):313-316.
13. Rohde J, Heitman J, Cardenas ME: The TOR kinases link nutrient sensing to cell growth. J Biol Chem (2001) 276(13):9583-9586.
14. Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (1975) 28(10):721-726.
15. Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (1975) 28(10):727-732.
16. Baker H, Sidorowicz A, Sehgal SN, Venzina C: Rapamycin (AY-22989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (1978) 31(6):539-545.
17. Martel RR, Klicius J, Galet S: Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol (1977) 55(1):48-51.
18. Houchens DP, Ovejera AA, Riblet SM, Slagel DE: Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol (1983) 19(6):799-805.
19. Elit L: CCI-779 Wyeth. Curr Opin Investig Drugs (2002) 3(8):1249-1253.
20. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 346(23):1773-1780.
21. Ocain TD, Longhi D, Steffan RJ, Caccese RG, Sehgal SN: A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. Biochem Biophys Res Commun (1993) 192(3):1340-1346.
22. Borel JF: Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology (1976) 31(4):631-641.
23. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, physico-chemical and biological characteristics. J Antibiot (1987) 40(9):1249-1255.
24. Tropschug M, Barthelmess IB, Neupert W: Sensitivity to cyclosporin A is mediated by cyclophilin in Neurospora crassa and Saccharomyces cerevisiae. Nature (1989) 342(6252):953-955.
25. Foor F, Parent SA, Morin N, Dahl AM, Ramadan N, Chrebet G, Bostian KA, Nielsen JB: Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from α-factor arrest in yeast. Nature (1992) 360(6405):682-684.
26. Parent SA, Nielsen JB, Morin N, Chrebet G, Ramadan N, Dahl AM, Hsu M-J, Bostian KA, Foor F: Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. J Gen Microbiol (1993) 139(Pt 12):2973-2984.
27. Breuder T, Hemenway CS, Movva NR, Cardenas ME, Heitman J: Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. Proc Natl Acad Sci USA (1994) 91(12):5372-5376.
28. De Tran QH, Guay E, Chartier S, Tousignant J: Tacrolimus in dermatology. J Cutan Med Surg (2001) 5(4):329-335.
29. Nakagawa H, Etoh T, Yokota Y, Ikeda F, Hatano K, Teratani N, Shimomura K, Mine Y, Amaya T: Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest (1996) 12(6):244-250.
30. Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, Sigal NH: The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 176(3):751-760.
31. Rotonda J, Burbaum JJ, Chan HK, Marcy AI, Becker JW: Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. J Biol Chem (1993) 268(11):7607-7609.
32. Becker JW, Rotonda J, McKeever BM, Chan HK, Marcy AI, Widerrecht G, Hermes JD, Springer JP: FK-506-binding protein: Three-dimensional structure of the complex with the antagonist L-685818. J Biol Chem (1993) 268(15):11335-11339.
33. Dromer F, Ronin O, Dupont B: Isolation of Cryptococcus neoformans var gattii from an Asian patient in France: Evidence for dormant infection in healthy subjects. J Med Vet Mycol (1992) 30(5):395-397.
34. Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM: HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection. AIDS (1998) 12(12):1491-1494.
35. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A: Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun (2000) 68(2):832-838.
36. Husain S, Wagener MM, Singh N: Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis (2001) 7(3):375-381.
37. Garbino J, Kolarova L, Lew D, Hirschel B, Rohner P: Fungemia in HIV-infected patients: A 12-year study in a tertiary care hospital. AIDS Patient Care STDS (2001) 15(8):407-410.
38. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ et al: Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 33(5):690-699.
39. Hooper DC, Pruitt AA, Rubin RH: Central nervous system infection in the chronically immunosuppressed. Medicine (1982) 61(3):166-188.
40. Jabbour N, Reyes J, Kusne S, Martin M, Fung J: Cryptococcal meningitis after liver transplantation. Transplantation (1996) 61(1):146-149.
41. Pappas PG: Therapy of cryptococcal meningitis in non-HIV-infected patients. Curr Infect Dis Rep (2001) 3(4):365-370.
42. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG,Reingold AL, Rimland D, Warnock DW: Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 45(11):3065-3069.
43. Cruz MC, Cavallo LM, Görlach JM, Cox G, Perfect JR, Cardenas ME, Heitman J: Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 19(6):4101-4112. A genetic and molecular examination of the role of Tor and FKBP12 on the activity on rapamycin in C neoformans pointing to a conserved role for these proteins.
44. Perfect JR, Durack DT: Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun (1985) 50(1):22-26.
45. Mody CH, Toews GB, Lipscomb MF: Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model. Infect Immun (1988) 56(1):7-12.
46. Mody CH, Toews GB, Lipscomb MF: Treatment of murine cryptococcosis with cyclosporin A in normal and athymic mice. Am Rev Respir Dis (1989) 139(1):8-13.
47. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J: Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J (1997) 16(10):2576-2589.
48. Arndt C, Cruz MC, Cardenas ME, Heitman J: Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. Microbiology (1999) 145(Pt 8):1989-2000.
49. Wang P, Cardenas ME, Cox GM, Perfect JR, Heitman J: Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of Cryptococcus neoformans. EMBO Rep (2001) 2(6):511-518.
50. Fox DS, Cruz MC, Sia RA, Ke H, Cox GM, Cardenas ME, Heitman J: Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol Microbiol (2001) 39(4):835-849.
51. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743873) with calcineurin inhibitors FK506 and L-685818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 44(3):739-746. This paper explores the synergism between FK-506 and L-685818 with currently used antifungal drugs, including azoles, pneumocandins and the vacuola proton-translocating-ATPase inhibitor bafilomycin against C neoformans.
52. Odds FC: Candida and Candidosis: A Review and Bibliography. 2nd Edition. Bailliere Tindall, London, UK (1988).
53. Beck-Sague CM, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal injections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis (1993) 167(5):1247-1251.
54. Stone EA, Fung HB, Kirschenbaum HL: Caspofungin: An echinocandin antifungal agent. Clin Ther (2002) 24(3):351-377.
55. Ellis D: Amphotericin B: Spectrum and resistance. J Antimicrob Chemother (2002) 49(Suppl 1):7-10.
56. Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S: Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J Antimicrob Chemother (1998) 42(6):747-753. First report of synergy between FK-506 and fluconazole or itraconazole against C albicans.
57. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D: Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 44(9):2373-2381. First report of antifungal synergy between CsA and fluconazole.
58. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P: Fluconazole plus cyclosporine: A fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 44(11):2932-2938. In vivo evidence for the utility of the synergy between azoles and calcineurin inhibitors in a rat model of endocarditis.
59. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol (2002) 46(1):257-268.
60. Bonilla M, Nastase KK, Cunningham KW: Essential role of calcineurin in response to endoplasmic reticulum stress. EMBO J (2002) 21(10):2343-2353.
61. Onyewu C, Blankenship JR, Poeta MD, Heitman J: Erogosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors in Candida albicans, Candida glabrata and Candida krusei. Antimicrob Agents Chemother (2003) 47: in press.
62. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (1996) 33(1):23-32.
63. Denning DW: Invasive aspergillosis. Clin Infect Dis (1998) 26(4):781-803.
64. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis (1996) 23(3):608-615.
65. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U et al: An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 37(2):173-180.
66. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 347(6):408-415.
67. Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 34(7):909-917.
68. High KP: The antimicrobial activities of cyclosporine, FK506 and rapamycin. Transplantation (1994) 57(12):1689-1700.
69. High KP, Washburn RG: Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J Infect Dis (1997) 175(1):222-225.
70. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Felming MA, Caron PR, Hsiao K, Navia MA: X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell (1995) 82(3):507-522.
71. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showater RE, Moomaw EW, Gastinel LN et al: Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature (1995) 378(6557):641-644.
72. Choi J, Chen J, Schreiber SL, Clardy J: Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 273(5272):239-242.
73. Jin L, Harrison SC: Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci USA (2002) 99(21):13522-13526. This paper shows the crystal structure of calcineurin-cyclosporin-cyclophilin complex with detailed structural comparisons to unbound calcineurin and unbound prodrug.
74. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, Ke H: Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci USA (2002) 99(19):12037-12042. Crystal structure of calcineurin-cyclosporin-cyclophilin complex with detailed structural comparisons to unbound calcineurin, unbound prodrug, calcineurin in complex with FKBP12-FK506 and comparisons of CsA to analogs with implications for calcineurin and cyclophilin binding.